[7]
Dang, Q.; Van Poelje, P.D.; Erion, M.D. The discovery and
development of MB07803, a second-generation fructose-
1,6-bisphosphatase inhibitor with im-proved pharmacokinetic
properties, as a potential treatment of type 2 diabetes
in: New therapeutic strategies for type 2 diabetes: small
molecule approaches. In: The Royal Society of Chemistry;
11306-323., 2012; pp. 306-322.
[15]
Dang, Q.; Kasibhatla, S. R.; Reddy, K. R.; Erion, M. D.; Reddy, M. R.; Agarwal, A. Preparation of heteroaromatic
phosphonates as fructose 1,6-bisphosphatase inhibitors.
PCT Pat., WO 2000014095 A1 March 16, 2000.
[16]
Erion, M. D.; Vanpoelje, P. A. A combination of fructose-
1,6-bisphosphatase (FBPase) inhibitors and insulin sensitizers
for the treatment of diabetes. PCT Pat., 2000. WO
2000038666 A2 20000706.
[17]
Bookser, B. C.; Dang, Q.; Reddy, K. R. Preparation of
arylheterocycle phosphates as antidiabetics and aryl
fructose-1,6-bisphosphatase inhibitors. Int. Patent Appl.,
WO2001066553, 2000.
[18]
Dang, Q.; Kasibhatla, S.R.; Reddy, K.R.; Erion, M.D.; Reddy, M.R.; Agarwal, A. Preparation of heteroaromatic
phosphonates as fructose 1,6-bisphosphatase inhibitors.
U.S. Patent US 6489476 B1, December 03, 2002.
[19]
Bauer, P.H.; Wright, S.W.; Schnur, R.C. Preparation of 4-
phenylaminoquinazoline derivatives as fructose 1,6-
bisphosphatase inhibitors. U.S. Patent US 20030144308
A1, July 31, 2007.
[20]
Yoshida, T.; Okuno, A. Fructose 1,6-bisphosphatase inhibitors
as preventives for the onset of diabetes. PCT Patent
WO 2004009118 A1, January 29, 2004.
[21]
Erion, M.D.; Van Poelje, P.D. Preparation of 2-(5-
phosphono)furanyl substituted heteroar-omatic compounds
as fructose-1,6- bisphosphatase (FBPase) inhibitors for use
in combination with insulin sensitizers for the treatment of
diabetes. US Patent, US 6756360 B1, June 29, 2004.
[22]
Yoshida, T.; Okuno, A. fructose 1,6-bisphosphatase
(FBPase) inhibitor preventative agents for diabetes mellitus
and related Conditions. US Patent, US 20050187194 A1,
August 25, 2005.
[23]
Dang, Q.; Kopcho, J.J.; Hecker, S.J.; Ugarkar, B.G. Preparation of thiazole compounds as fructose 1,6-
bisphosphatase inhibitors. PCT Patent, WO 2006023515
A2, March 2, 2006.
[24]
Carniato, D.; Arbellot, A.; Moinet, G.; Audet, A.; Botton, G. Preparation of imidazolylmethylbenzoates as fructose-
1,6-bisphosphatase inhibitors. Eur. Pat., EP 1752450 A1,
February 14, 2007.
[25]
Gubler, M.; Haap, W.; Hebeisen, P.; Kitas, E.A.; Kuhn, B.; Minder, R.E.; Schott, B.; Wessel, H.P. Preparation of sulfonylureido
thiazoles as fructose-1,6-bisphosphatase
(FBPase) inhibitors for the treatment of diabetes. PCT Patent,
WO 2007137962 A1, December 06, 2007.
[26]
Reddy, R. K.; Erion, M. D.; Dang, Q. Preparation of azabenzimidazole
derivatives as prodrug inhibitors of fructose
1,6-bisphosphatase. PCT Patent, WO 2008019309 A, February
14, 2008.
[27]
Botton, G.; Leriche, C.; Arbellot, A.; Audet, A.; Gleitz, J. Preparation of 1H-benzimidazol-5-yl-3,6-dihydro-2H-1,3,4-
thiadiazin-2-one derivatives as inhibitors of fructose-1,6-
bisphosphatase, and their pharmaceutical compositions for
treating diseases associated with insulin resistance syndrome
especially diabetes. PCT Patent, WO 2009062576
A2, May 22, 2009.
[28]
Haap, W.; Hebeisen, P.; Kitas, E.A.; Kuhn, B.; Mohr, P.; Wessel, H.P. Preparation of pyridine compounds as fructose-
1,6-bisphosphatase inhibitors for use in treating diseases
such as diabetes. PCT Patent, WO 2009068468 A2,
June 04, 2009.
[29]
Hebeisen, P.; Kitas, E.A.; Minder, R.E.; Mohr, P.; Wessel, H.P. Preparation of aminothiazole derivatives as fructose-
1,6-bisphosphatase inhibitors for treating diseases such as
diabetes. PCT Patent, WO 2009068467 A1, June 04, 2009.
[30]
Kantrowitz, E.R.; Heng, S. Dibenzofuran derivatives as
fructose 1,6-biphosphatase inhibitors and their preparation
and use in mono and combina-tion therapy of type 2 diabetes.
PCT Patent, WO 2010091185 A2. August 12, 2010.
[31]
Li, J.; Tang, J.; Li, J.; He, H.; Gao, L.; Yang, F.; Yang, L.; Yusupu, A. Preparation of 2,5-diaryl-1,3,4-oxadiazole compounds
for treating type II diabetes. China Patent, CN
102924399 A, February 13, 2013.
[32]
Wan, J.; Han, X.; Chen, H.; Zhu, H.; Feng, L.; Ren, Y.; Chi, B. Application of nitrostyrene derivatives for inhibiting
fruc-tose-1,6-bisphosphatase. China Pat., CN 104146989
A, November 19, 2014.
[62]
Triscari, J.; Walker, J.; Feins, K.; Tao, B.; Bruce, S.R. In multiple ascending dose of CS-917, a novel fructose 1,6-bisphosphatase (FBPase) Inhibitor, in subjects with type 2 diabetes treated for 14 days; American Diabetes Association: Alexandria, VA, 2006.
